Variables | All patients | Women | Men | Â |
---|---|---|---|---|
n = 285 | n = 124 | n = 161 | p valuea | |
Age (years) | 42 (32, 51; 18–59) | 41 (30, 50() | 43 (32, 52) | 0.10 |
Diabetes duration (years) | 20 (11, 30; 1–55) | 19 (11, 29) | 21 (11, 32) | 0.27 |
Gal3BP b (mg/l) | 2.3 (1.8, 3.1; 0.8–8.9) | 2.6 (1.9, 3.6) | 2.1 (1.6, 2.8) | < 0.001 |
sCD163 (mg/l) c | 0.4 (0.3, 0.5; 0.2–1.9) | 0.4 (0.3, 0.6) | 0.4 (0.3, 0.5) | 0.78 |
Galectin-3 (μg/l) | 0.9 (0.6–1.7; 0.001–100) | 0.9 (0.5, 1.4) | 0.9 (0.6, 2.0) | 0.15 |
HbA1c | ||||
 mmol/mol | 63 (54, 71; 25–110) | 64 (54, 72) | 63 (54, 69) | 0.33 |
 % | 7.9 (7.1, 8.6; 4.4–12.2) | 8.0 (7.1, 8.7) | 7.9 (7.1, 8.5) | |
Total cholesterol (mmol/l) | 4.6 (4.1, 5.1; 2.1–10.9) | 4.6 (4.1, 5.4) | 4.5 (4.0, 5.1) | 0.13 |
Triglycerides (mmol/l) | 0.9 (0.7, 1.3; 0.1–5.9) | 0.8 (0.6, 1.3) | 0.9 (0.7, 1.3) | 0.32 |
LDL-cholesterol (mmol/l) | 2.8 (2.4, 3.3; 0.6–8.3) | 2.8 (2.4, 3.4) | 2.8 (2.4, 3.3) | 0.79 |
HDL-cholesterol (mmol/l) | 1.5 (1.3, 1.8; 0.3–2.7) | 1.6 (1.4, 1.9) | 1.4 (1.2, 1.7) | 0.003 |
Creatinine (μmol/l) d | 70 (62, 182; 28–182) | 62 (54, 70) | 74 (68, 82) | < 0.001 |
Abdominal obesity e | 47 (17) | 34 (28) | 13 (8) | < 0.001f |
General obesity g | 34 (12) | 22 (18) | 12 (8) | 0.009 f |
Systolic BP (mmHg) | 20 (110, 130; 90–160) | 120 (110, 130) | 125 (120, 130) | < 0.001 |
Diastolic BP (mmHg) | 70 (70, 76; 55–100) | 70 (65, 75) | 70 (70, 80) | < 0.001 |
Smoking h | 27 (10) | 10 (9) | 17 (11) | 0.55 f |
Physical inactivity i | 29 (11) | 12 (10) | 17 (11) | > 0.99 f |
Depression | 30 (10) | 14 (11) | 16 (10) | 0.85 f |
Cardiovascular complications | 10 (4) | 4 (3) | 6 (4) | > 0.99 f |
Diabetes retinopathy j | 205 (72) | 88 (72) | 117 (73) | 0.79 f |
Foot complications k | 47 (17) | 13 (11) | 34 (22) | 0.023 f |
Antidepressants | 23 (8) | 12 (10) | 11 (7) | 0.39 f |
Antihypertensive drugs | 96 (34) | 35 (28) | 61 (38) | 0.10 f |
Lipid lowering drugs | 133 (47) | 55 (44) | 78 (48) | 0.55 f |